Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Lilly's Verzenio® (abemaciclib) increases overall survival in HR+, HER2-, high-risk early breast cancer with two years of therapy
06:45am, Wednesday, 27'th Aug 2025
Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year
Citi's Geoff Meacham on Eli Lilly's stock climbing as weight loss pill clears latest trial
06:21pm, Tuesday, 26'th Aug 2025
Geoff Meacham, Citi Research Managing Director, joins 'Fast Money' to talk competition in the weight loss drug space as Eli Lilly's weight loss pill clears its latest trial.
S&P 500 Gains and Losses Today: Eli Lilly Stock Soars as Weight-Loss Pill Shows Promise; Beverage Makers Face Pressure
05:20pm, Tuesday, 26'th Aug 2025
Major U.S. equities indexes ticked higher as investors looked past concerns about President Donald Trump's effort to remove Federal Reserve Governor Lisa Cook and ahead to Wednesday's Nvidia earnings
Why Eli Lilly Stock Trounced the Market on Tuesday
04:46pm, Tuesday, 26'th Aug 2025
There's nothing like a successful clinical trial of a high-potential medicine to blast a pharmaceutical company's stock price higher. That was the dynamic behind Eli Lilly's (LLY 5.67%) nearly 6% gain
Healthy Returns: Eli Lilly's chief scientific officer breaks down the latest obesity pill data
03:01pm, Tuesday, 26'th Aug 2025
Eli Lilly's Daniel Skovronsky talks the latest orforglipron trial, while UnitedHealth Group CEO Stephen Hemsley is moving quickly on a strategic turnaround.
Eli Lilly Stock Jumps On Weight-Loss Pill Trial
01:26pm, Tuesday, 26'th Aug 2025
Eli Lilly and Co. LLY stock has experienced significant volatility over the past six months, primarily driven by reactions to developments in its weight-loss drug portfolio.
Durable Goods Orders Decreased Less Than Expected
12:21pm, Tuesday, 26'th Aug 2025
Pre-market activity is somewhat better than earlier in the trading session this morning, following a less-bad Durable Goods report for July. We also appear to be bouncing around a bit more in recent t
Top Stock Movers Now: Eli Lilly, EchoStar, Constellation Brands, and More
12:10pm, Tuesday, 26'th Aug 2025
U.S. equities were little changed at midday on limited market-driving corporate earnings news and economic data. The Dow Jones Industrial Average, S&P 500, and Nasdaq all moved by small amounts.
Eli Lilly's Obesity Pill Moves Closer to Approval
12:06pm, Tuesday, 26'th Aug 2025
Eli Lilly & Co.'s experimental obesity pill helped patients lose 9.6% of their body weight in a trial that moves the company one step closer to a potential approval. Damian Garde has more on "Bloomber
Guggenheim Partner's Seamus Fernandez: Oral weight loss pill 'meaningful step up' for Eli Lilly
11:35am, Tuesday, 26'th Aug 2025
Seamus Fernandez, Guggenheim Partners biotech analyst, joins CNBC's 'Squawk on the Street' to discuss the latest data on Eli Lilly's obesity pill.
LLY Weight Loss Drug Momentum, AT&T's (T) $23B EchoStar Licenses, ULTA Price Target Hikes
11:30am, Tuesday, 26'th Aug 2025
AT&T (T) secured a deal worth $23 billion with EchoStar (SATS) to buy spectrum licenses from the company. Eli Lilly (LLY) tacked on billions of dollars in market share after its experimental weight lo
Eli Lilly advances weight loss pill towards regulatory submissions after successful trial
11:01am, Tuesday, 26'th Aug 2025
Eli Lilly and Co (NYSE:LLY) shares moved higher Tuesday after the company reported positive late-stage trial results for its experimental oral obesity and diabetes drug, orforglipron. The Phase 3 stud
Eli Lilly Stock Climbs on Weight-Loss Drug Trial Results
10:52am, Tuesday, 26'th Aug 2025
Shares of pharmaceutical giant Eli Lilly and Co (NYSE:LLY) are on the rise today, up 3.7% at $720.07 at last check.
Eli Lilly Stock Rises as Firm Plans to Ask for Weight-Loss Pill Approval
10:45am, Tuesday, 26'th Aug 2025
Eli Lilly (LLY) shares gained more than 4% soon after the opening bell Tuesday as results from a new study moved the drugmaker closer to applying for approval of its experimental weight-loss pill.
Cramer's Stop Trading: Eli Lilly
10:19am, Tuesday, 26'th Aug 2025
Jim Cramer breaks down why he's keeping an eye on shares of Eli Lilly.
